2nd November 2014, Frankfurt, Germany: Phynova held 22 face-to-face meetings at BIO-Europe, the largest partnering conference in Europe for the global biotechnology industry that was held during 2-5 November at Frankfurt, Germany. There was a lot of interest in Melokinex™, Phynova’s lead pharma product and this demonstrates that there is a significant gap in the market for a product like Melokinex™ for post-operative ileus (POI).
Phynova’s first product filed under the Traditional Medicinal Products Directive, Phynova Joint and Muscle Relief Tablets™, was of interest to several companies searching for new branded OTC opportunities.
Phynova Business Development is currently following up with the interested parties in order to expedite the route to market for these new product opportunities.
About post-operative ileus (POI): POI is a temporary dismotility of the GI tract following surgery. The condition is accepted as an ineveitable complication of major surgery. The incidence of POI following abdominal surgery is 6.3-10.7%. Substantial economic burden is associated with POI due to increase in hospitalisation time by several days.
About the Meeting: BIO-Europe® is Europe’s largest partnering conference serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies. Produced with the support of BIO, it is regarded as a “must attend” event for the biotech industry. http://www.ebdgroup.com/bioeurope/index.php